PRC
MYGN icon

Pearl River Capital’s Myriad Genetics MYGN Stock Holding History

Pearl River Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-882
Closed -$30K – 417
2019
Q1 		$30K Buy
882
+536
+155% +$16.3K 0.07% 275
2018
Q4 		$10K Buy
+346
New +$12.4K 0.05% 557

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pearl River Capital's MYGN Position: Q2 2019 in Review

Pearl River Capital sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 882 shares — an estimated $30K sold.

Pearl River Capital first reported a position in MYGN in Q4 2018 and held it in 2 quarters. The position peaked at $30K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Pearl River Capital reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 882 Myriad Genetics shares in Q2 2019, an estimated $30K.
  • Pearl River Capital first reported a position in Myriad Genetics in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Myriad Genetics position peaked at $30K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.